ConductScience.org, home

Comparison · NCT00965991-a2091075

Metformin vs Glyburide: Number of Participants Assessed for Glucose Control

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Metformin vs Glyburide: Number of Participants Assessed for Glucose Control. Trial comparisons, record NCT00965991-a2091075. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00965991-a2091075

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.6670.5540.763wilson
Risk in group 20.6760.5630.771wilson
Risk difference, group 1 minus group 2-0.00901-0.1570.139newcombe hybrid score
Risk ratio, group 1 over group 20.9870.7881.24log
Odds ratio, group 1 over group 20.960.4851.9log
Number needed to treat, for one fewer participant with the outcome on Metformin than on Glyburide111from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Metforminmetformin: patients received glyburide initial dose of 500 mg PO BID. Increased as necessary to a maximum dose of 2000 mg QD to control blood glucose5075OG000
Group 2GlyburideGlyburide: Initial dose of 2.5mg PO BID increased as necessary to a maximum dose of 20 mg (10mg BID) QD to control blood glucose5074OG001

Outcome

Type
PRIMARY
Title
Number of Participants Assessed for Glucose Control
Description
The importance of exercise in the management of blood glucose was emphasized, and 30 minutes of walking per day was recommended. Patients received instruction from a nurse educator or a certified diabetes educator regarding diet and the use of the glucometer. Number of participants with a glucose level \<100 mg/dL.
Time frame
fasting and 2 hour postprandial blood glucose
Population

Source ClinicalTrials.gov

Trial

Title
Metformin Compared to Glyburide in Gestational Diabetes
NCT number
NCT00965991
Phases
NA
Conditions
Gestational Diabetes
Interventions
metformin, Glyburide
Lead sponsor
University of New Mexico
Results first posted
2023-12-21

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00965991-a2091075